Using deep learning to assist readers during the arbitration process: a lesion-based retrospective evaluation of breast cancer screening performance

Laura Kerschke 1 · Stefanie Weigel 2 · Alejandro Rodriguez-Ruiz 3 · Nico Karssemeijer 3,4 · Walter Heindel 2

Received: 12 March 2021 / Revised: 4 June 2021 / Accepted: 13 July 2021 / Published online: 12 August 2021
© The Author(s) 2021

Abstract

Objectives To evaluate if artificial intelligence (AI) can discriminate recalled benign from recalled malignant mammographic screening abnormalities to improve screening performance.

Methods A total of 2257 full-field digital mammography screening examinations, obtained 2011–2013, of women aged 50–69 years which were recalled for further assessment of 295 malignant out of 305 truly malignant lesions and 2289 benign lesions after independent double-reading with arbitration, were included in this retrospective study. A deep learning AI system was used to obtain a score (0–95) for each recalled lesion, representing the likelihood of breast cancer. The sensitivity on the lesion level and the proportion of women without false-positive ratings (non-FPR) resulting under AI were estimated as a function of the classification cutoff and compared to that of human readers.

Results Using a cutoff of 1, AI decreased the proportion of women with false-positives from 89.9 to 62.0%, non-FPR 11.1% vs. 38.0% (difference 26.9%, 95% confidence interval 25.1–28.8%; p < .001), preventing 30.1% of reader-induced false-positive recalls, while reducing sensitivity from 96.7 to 91.1% (5.6%, 3.1–8.0%) as compared to human reading. The positive predictive value of recall (PPV-1) increased from 12.8 to 16.5% (3.7%, 3.5–4.0%). In women with mass-related lesions (n = 900), the non-FPR was 14.2% for humans vs. 36.7% for AI (22.4%, 19.8–25.3%) at a sensitivity of 98.5% vs. 97.1% (1.5%, 0–3.5%).

Conclusion The application of AI during consensus conference might especially help readers to reduce false-positive recalls of masses at the expense of a small sensitivity reduction. Prospective studies are needed to further evaluate the screening benefit of AI in practice.

Key Points

• Integrating the use of artificial intelligence in the arbitration process reduces benign recalls and increases the positive predictive value of recall at the expense of some sensitivity loss.
• Application of the artificial intelligence system to aid the decision to recall a woman seems particularly beneficial for masses, where the system reaches comparable sensitivity to that of the readers, but with considerably reduced false-positives.
• About one-fourth of all recalled malignant lesions are not automatically marked by the system such that their evaluation (AI score) must be retrieved manually by the reader. A thorough reading of screening mammograms by readers to identify suspicious lesions therefore remains mandatory.

Keywords Breast cancer · Screening · Mammography · Artificial intelligence
Abstracts

Introduction

As more deep learning–based artificial intelligence (AI) mammography screening tools enter the clinical market, greater focus will be placed on scientific validation in diverse settings [1]. In digital mammography reader studies, AI demonstrated the ability to significantly reduce radiologists’ workload, improve specificity, and reach a cancer detection rate comparable to radiologists [1–6].

However, clinical validation is lacking, and it is not clear how the power of deep learning should be used to optimize practice [7]. Most of the previous works were based on retrospectively selected, cancer-enriched data sets that do not reflect the setting of a population-based screening program in practice, where cancer prevalence is much lower [8]. Translation of retrospective findings resulting from a particular experimental setting to different steps of the screening process remains mainly unclear [9]. Furthermore, only few studies took the localization accuracy of the AI system into account, to verify that a location-level false-positive and false-negative finding on the same mammogram do not result in a true-positive rating on the image level [6, 8, 10].

False-positive results are a negative side effect of mammography screening [11, 12]. As most screening examinations are finally negative, AI might be useful to increase the specificity and positive predictive value of recall (PPV-1) by reducing reader-induced false-positive results [10]. In Germany, independent double-reading with arbitration results in up to 25% of all examinations being discussed in a consensus conference by the first and second reader together with a third reader. Most of the cases discussed are dismissed during the arbitration process leading to recommendation of regular biennial screening. Finally, recall recommendation is given in 41 out of 1000 women screened, to diagnose 6 women with breast cancer [13, 14]. In contrast, in the Netherlands, a lower recall rate of 21 out of 1000 women screened is reported together with a comparable cancer detection rate [15].

There is no evidence from the literature how AI may help guiding human decision during the arbitration process on whether a suspicious mammographic lesion requires further diagnostic workup. Before using AI prospectively with the aim to lower false-positive recalls, it seems mandatory to scientifically evaluate its performance retrospectively in a real-world dataset of consecutive recall examinations from a population-based screening program. The subset of women that undergo recall assessments provides particularly high-quality data with accurate lesion-based ground-truth labels due to further imaging procedures, histologic workup (if indicated) and 2-year follow-up for interval cancers.

The purpose of the study is to evaluate if a deep learning–based AI system can discriminate benign from malignant mammographic screening abnormalities that led to recall recommendation following double-reading with arbitration, to reduce assessments of benign findings and increase the PPV-1.

Materials and methods

This retrospective study was conducted with consecutive digital mammographic screening examinations obtained between 2011 and 2013 at the Reference Screening Unit Muenster, Germany. The study was approved by the local ethics committee (Ärztekammer Westfalen-Lippe and University of Muenster, Germany). Informed consent was not required for the evaluation of internal anonymized data.

Screening setting

The national mammography screening program in Germany is based on European guidelines [13]. The target population includes women aged 50 to 69 years who are invited biennially. The program comprises masked independent readings of two-view 2D digital mammograms by two certified physician readers. Qualifications have been described in detail elsewhere [16]. Prior to recall recommendation, suspicious findings of one or both readers have to be discussed in a consensus conference (arbitration process) by both readers together with a third physician, who performs the centrally organized assessment [17].

Study setting

During the screening period 2011 to 2013, a total of 41,722 digital mammography examinations were obtained by two vendors (MicroDose Mammography (L30), Philips Medical Systems: Inspiration, Siemens Healthineers). Five readers with more than five years of experience in breast imaging performed the independent double readings. Recall recommendation was finally given at the consensus conference in 2957 women. Screening data of recalled women (including breast density, radiological lesion features assessed at the consensus conference and assessment reports), documented at the time of screening, were retrospectively derived from the screening documentation software MaSc.

One hundred thirty-four (0.3%) of all recall recommendations were based on clinical or technical reasons and were excluded from this study. Two thousand eight hundred...
twenty-three (6.7%) recalls resulted from mammographic abnormalities. Of the 2,823 mammographic recalls, 566 were excluded due to computed radiography (CR) technique (\(n = 436\)), breast implants (\(n = 2\)), loss to assessment (\(n = 26\)), or missing reference standard information (RSI) (\(n = 102\)), resulting in 2257 examinations included in the study (Fig. 1). The RSI included assessment participation with bilateral ultrasound plus, if indicated, additional mammographic views, the completion of follow-up examinations and invasive procedures (e.g., additional breast surgery after minimally invasive tissue sampling), and the information of the cancer registry on interval cancers. Interval cancers were defined as invasive breast cancers and ductal carcinoma in situ (DCIS) occurring within 24 months after negative screening participation. Histological evaluation after minimal invasive biopsies within the screening program were performed by three certified pathologists [16], with 5 to > 15 years of experience in breast pathology.

**Performance evaluation of human readers and AI**

For study purposes, recalled mammographic lesions were defined malignant (i.e., reader true-positive), if a histologically confirmed invasive breast cancer or DCIS was diagnosed at the specific lesion location (defined at the consensus conference) within the screening program (recall assessment) or the 24-month interval after a negative assessment. Otherwise, recalled lesions were defined benign (i.e., reader false-positive).

Therefore, each recalled lesion was relocated by one of the screening readers in the corresponding screening mammograms based on the original screening documentation. The AI software Transpara (version 1.5.0, ScreenPoint Medical) was used to obtain a region-based integer-valued score (0, 27, 28, ..., 95) for each recalled lesion. This was realized either by automatically placed lesion marks or, if not automatically marked by AI, by manually clicking on the lesion in order to obtain a circle around the lesion (varying lesion-dependent in size). The software is a commercial product using deep learning convolutional neural networks to automatically detect regions suspicious of breast cancer in mammograms [3, 4, 18]. Version 1.5.0 of the software was trained and tested based on a proprietary database of approximately 200,000 2D mammograms (including 10,000 malignant and 5,000 benign), including images from devices of five different vendors (Hologic, Siemens Healthineers, GE Healthcare, Philips, Fujifilm Healthcare) collected at multiple institutions across Europe, the USA, and Asia. For each automatically detected finding in a mammogram, the software (internally) assigns a score from 1 to 100. For AI findings that are graded 95–100, a score of 95 is displayed for the user. For AI findings that are graded 1–26 and all regions without AI findings, no score is
Recalled lesions for which no score was displayed were therefore assigned a value of 0 (Fig. 2a–c). If a lesion was visible in both views (cranio-caudal, medio-lateral-oblique), the higher score was used for the evaluation. Based on the (internal) region scores, the software always displays an overall score between 1 and 10 for the whole examination (not considered in the evaluation). We performed a lesion-based analysis using the specific region score of each recalled lesion to account for potential location-level false-positives and false-negatives (Fig. 2c–d). For each possible cutoff 0, 1, 27, ..., 96, recalled malignant and recalled benign lesions for which the AI score exceeded the respective cutoff were evaluated as AI true-positives and false-positives, respectively. Recalled malignant and recalled benign lesions for which the score did not exceed the cutoff were evaluated as AI false-negatives and true-negatives, respectively.

Further, malignant lesions of recalled patients that were additionally detected during assessment or the 24-month interval after a negative assessment (independent of a visibility on the screening mammogram) were generally evaluated as false-negatives in all sensitivity calculations (both under human and AI reading).

As each recalled women can be affected by more than one mammographic lesion, false-positives can occur both in breast cancer-negative and in breast cancer-positive women.

Statistical analyses

Following the free-response paradigm [19], the primary endpoints of the study were:

- the proportion of women without any false-positive ratings out of all women (including women with true-positive lesions), termed non-false-positive rate (non-FPR), and
the related lesion-specific sensitivity, defined as proportion of detected malignant lesions (i.e., true-positives) out of all malignant lesions.

Notice that the non-FPR is in principle a specificity measurement adapted to the situation of (possibly) multiple lesions per patient. The primary endpoints were estimated as a function of the classification cutoff for the AI score. A two-sided 95% confidence interval (CI) according to Tango [20] was obtained to estimate the difference in the non-FPRs resulting under human and targeted AI reading based on the cutoff of 1 that led to the lowest decrease in the lesion-specific sensitivity, while increasing the non-FPR under AI reading as compared to human reading. The non-FPRs were compared using McNemar’s Test. Furthermore, a 95% CI for the difference in the lesion-specific sensitivities was calculated by non-parametric bootstrap. A 95% CI for the difference in the PPV-1 was determined using the Kosinski method [21]. Sensitivity and non-FPR were additionally analyzed in the two subgroups of women with reader-identified mass- or calcification-related lesions (with these lesions potentially showing additional lesion type characteristics, e.g., calcification + asymmetry).

Women with at least one lesion not presenting as mass or calcification, respectively, were not included in the subgroups.

Statistical analyses were performed with R, version 4.0.2. \( p \) values were interpreted in Fisher’s sense, representing a metric weight of evidence against the null hypothesis of no effect. \( p < .05 \) was considered noticeable.

## Results

In total, 2257 women recalled for further assessment of 295 malignant and 2289 benign mammographic lesions were included (Fig. 1). Nine of these women were affected by 10 additional malignant lesions, 5 of which were detected during assessment, and 5 of which were detected as interval cancers during the 24-month follow-up interval (outside the screening program). Out of all recalled women, 293 were breast cancer positive (13.0%) and 1964 were breast cancer negative (87.0%). A screening-detected breast cancer (i.e., detection of at least one malignant lesion already identified during the arbitration process or during assessment) was diagnosed in 288 of the breast

### Table 1

| Variable                                      | All recalled women included | Women with screening-detected breast cancer | Women without breast cancer (incl. 2-year follow-up) | Women with an interval cancer (in 2-year follow-up) |
|-----------------------------------------------|-----------------------------|-------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Number (N)                                    | 2257                        | 288                                       | 1964                                                | 5                                                   |
| Age (years)                                   |                              |                                           |                                                     |                                                     |
| 50–54                                        | 1180 (52.3)                 | 86 (29.9)                                | 1093 (55.7)                                         | 1 (20.0)                                            |
| 55–59                                        | 409 (18.1)                  | 67 (23.3)                                | 340 (17.3)                                          | 2 (40.0)                                            |
| 60–64                                        | 384 (17.0)                  | 70 (24.3)                                | 314 (16.0)                                          | 0 (0.0)                                             |
| 65–69                                        | 284 (12.6)                  | 65 (22.6)                                | 217 (11.0)                                          | 2 (40.0)                                            |
| Screening round                               |                              |                                           |                                                     |                                                     |
| First                                         | 949 (42.0)                  | 71 (24.7)                                | 877 (44.7)                                          | 1 (20.0)                                            |
| Subsequent                                   | 1308 (58.0)                 | 217 (75.3)                               | 1087 (55.3)                                         | 4 (80.0)                                            |
| Mammography device                            |                              |                                           |                                                     |                                                     |
| Philips Microdose (L30)                       | 1512 (67.0)                 | 190 (66.0)                               | 1318 (67.1)                                         | 4 (80.0)                                            |
| Siemens Inspiration                           | 745 (33.0)                  | 98 (34.0)                                | 646 (32.9)                                          | 1 (20.0)                                            |
| Breast density category analogue to BI-RADS 4th ed. |                              |                                           |                                                     |                                                     |
| 1                                            | 38 (1.7)                    | 7 (2.4)                                  | 31 (1.6)                                            | 0 (0.0)                                             |
| 2                                            | 588 (26.1)                  | 85 (29.5)                                | 502 (25.6)                                          | 1 (20.0)                                            |
| 3                                            | 1491 (66.0)                 | 172 (59.7)                               | 1315 (67.0)                                         | 4 (80.0)                                            |
| 4                                            | 140 (6.2)                   | 24 (8.3)                                 | 116 (5.9)                                           | 0 (0.0)                                             |
| Surgical therapy                              |                              |                                           |                                                     |                                                     |
| Breast conserving therapy                     | –                           | 248 (86.1)                               | –                                                   | 0 (0.0)                                             |
| Mastectomy                                   | –                           | 21 (7.3)                                 | –                                                   | 0 (0.0)                                             |
| No surgery                                   | –                           | 4 (1.4)                                  | –                                                   | 0 (0.0)                                             |
| Missing                                      | –                           | 15 (5.2)                                 | –                                                   | 5 (100)                                             |

Data are presented as absolute frequencies with percentages in parentheses.
The ground truth in terms of cancer presence was determined based on histopathology and/or 24-month follow-up.
cancer positive women. Four of these women (2 of which were recalled for a malignant lesion, 2 of which were recalled for benign lesions only) were affected by at least one additional malignant lesion detected during assessment. An interval cancer occurred in 5 women, which were all recalled for a benign lesion only. Of the 2584 recalled lesions, 295 were malignant (11.4%), corresponding to 286 of 293 breast cancer positive women, and 2289 (88.6%) were benign, corresponding to 1,964 women without and 43 women with breast cancer. Patient- and lesion-specific characteristics are summarized in Tables 1 and 2.

Four of five malignant lesions diagnosed during interval (80%) were considered to be true interval cancers without signs of malignancy on the screening mammogram (Table 3).

Performance of original human reading

The lesion-specific sensitivity of independent double reading with arbitration was 96.7% (295 of 305 malignant lesions). In total, 11.1% (250 of 2257 women) had no false-positive rating. The PPV-1 was 12.8% (288 of 2257 women) (Table 4).

Performance of targeted AI reading

The distribution of recalled malignant and benign lesions as a function of the AI score is shown in Fig. 3. Of the 295 reader-detected malignant lesions, 105 (35.6%) were rated with a score exceeding 90, whereas 278 (94.2%) were rated higher than 0. The remaining 17 reader-detected malignant lesions (5.8%) were all rated with a score of 0 (see, e.g., Fig. 2c). In contrast, 761 (33.2%) of the 2289 recalled benign lesions (reader false-positives) were assigned a score of 0 (see, e.g., Fig. 2a–b) and 1528 (66.8%) were rated higher than 0. When activating the lesion localization function of the AI system, 223 of the 295 recalled malignant lesions (75.6%) and 522 of the 2289 recalled benign lesions (22.8%) were automatically marked.

The lesion-specific sensitivity and corresponding non-FPR of the AI system resulting under varying cutoffs for the AI score are shown in Fig. 4. Consistent with the results from Fig. 3, a cut off of 1 yielded the lowest decrease in the lesion-specific sensitivity from 96.7% (295 of 305 malignant lesions) to 91.1% (278 of 305 lesions), while increasing the non-FPR from 11.1% (250 of 2257 women) to 38.0% (857 of 2257 women) (difference: 26.9%; 95% CI 25.1–28.8%; p < .001) as compared to human reading (Table 4). The non-FPR improvement achieved by AI translated into an increase of the PPV-1 from 12.8% (288 out of 2257 women) to 16.5% (272 of 1649 women) (Table 4) and a reduction of 30.1% (592 of 1969 women) of reader-induced false-positive recalls.

Of the 295 reader-detected malignant lesions, 17 (5.8%) were missed by the AI system, corresponding to 17 women.
One of these women was affected by a further malignant lesion detected by AI, resulting in 16 breast cancer diagnoses that were lost on the patient level. Missed lesions included 7 (41.2%) DCIS (7.6% of all recalled DCIS lesions) and 10 (58.8%) invasive cancers (5.2% of all recalled invasive lesions) and were primarily characterized by mammographic signs of lower suspicion of malignancy. The majority of these lesions (70.6%) presented as calcifications (Table 3).

AI performance was highest in the subgroup of 900 women with mass-related lesions (lesion-specific sensitivity of original vs. AI reading: 97.8% vs. 96.4% [135 vs. 133 of 138 lesions]; non-FPR: 21.2% vs. 34.8% [140 vs. 230 of 660 women] original vs. AI reading) (Table 4).

**Discussion**

We assessed the diagnostic performance of a deep learning artificial intelligence (AI) system to predict malignancy of 2D mammographic lesions that led to a recall recommendation by independent double-reading with arbitration based on a real-world dataset of consecutive examinations from a
population-based screening program. Using the cutoff with lowest sensitivity loss, the AI system notably increased the proportion of women without false-positive ratings from 11.1 to 38.0% and improved the positive predictive value of recall (PPV-1) from 12.8 to 16.5% as compared to original human reading with arbitration. The improvement was observed at the expense of a sensitivity reduction on the lesion level from 96.7 to 91.1% (17 out of 295 reader-detected malignant lesions were missed by AI).

Several studies demonstrated the ability of AI to achieve better or comparable diagnostic performance to that of an average radiologist [10, 18], to improve radiologists’ performance when used in decision aid in a single-reading setting [3, 5, 6], or to reduce reading workload [4]. As false-positive results are an inherent risk of screening, causing additional diagnostic work-up, anxiety, and distress for the women involved [11, 12], the specificity and PPV-1 are important performance indicators of a screening program [13]. AI might help to increase these parameters.

Consistent with the literature [14], the majority of recalled women in our study sample were relatively young (50–54 years) and had heterogeneous breast tissue (ACR 3). The PPV-1 was 12.8%, which is in the middle field of ranges reported for other European countries (9.8–29%) [15, 22], and in line with the PPV-1 of the national screening program [14].

We focused on a lesion-based AI evaluation. More than 90% of recalled lesions were categorized by readers as low suspicious of malignancy (BI-RADS analogue 4a). The most frequent lesion characteristics (by decreasing frequency) were masses, calcifications, and densities. The majority of malignant lesions presented as calcifications and masses. Using a cutoff of 1, AI missed none of the 44 recalled malignant lesions categorized as highly suspicious (BI-RADS analogue 5). Most of the missed lesions were categorized as BI-RADS 4a (15 of 17) and presented as calcifications (12 of 17).

When focusing on the subgroup of women with mass-related lesions, sensitivity dropped from 97.8 to 96.4% (2 out of 135 reader-detected malignant lesions were missed), while the proportion of women without false-positive ratings increased from 14.2 to 36.7%.

To our knowledge, this is the first study evaluating targeted use of AI as a decision tool to discriminate benign from malignant mammographic lesions to guide indications for further mammography-related assessment. A particular strength of the study is the use of high-quality data of consecutive recalls from a population-based screening program with accurate lesion-based ground-truth labels obtained from standardized assessment and 2-year follow-up for interval cancers.

In a related study of Aboutalib et al. [23], a convolutional neural network was able to discriminate recalled benign mammographic images from negative exams and those with malignancy, suggesting that certain imaging features, potentially not identifiable by human readers, might induce false-positive recalls [23]. Due to the high complexity of deep neural networks, they could currently not further visualize these imaging features, providing a thorough clinical interpretation of them—interpretability of deep learning models is still one of the key challenges in AI research [24]. Furthermore, they did not assess how the performance of their system compares to that of radiologists on the same datasets.

In our study, the lesion localization function of the AI system automatically marked 75.6% of all recalled malignant lesions. Readers should be aware that subtle mammographic lesions found by trained readers are not automatically displayed by AI in about one-fourth of all recalled malignant lesions. Therefore, a thorough reading of screening mammograms by humans is not only required by law, but also necessary in view of the study results. If a suspicious lesion is detected by human reading, the AI system might be used to modify the final decision depending on the lesion-based score. This resulted in 5.8% of the reader-

| Performance measure | Original human reading | Targeted AI reading | Difference (95% CI) |
|----------------------|-----------------------|---------------------|---------------------|
| Lesion-specific sensitivity | 96.7% | 91.1% | 5.6% (3.1%, 8.0%) |
| Non-FPR | 11.1% | 38.0% | 26.9% (25.1%, 28.8%) |
| PPV-1 | 12.8% | 16.5% | 3.7% (3.5%, 4.0%) |
| Subgroup of women with mass-related lesions (n = 900 women) | | | |
| Lesion-specific sensitivity | 97.8% | 96.4% | 1.4% (0.0%, 3.5%) |
| Non-FPR | 14.2% | 36.7% | 22.4% (19.8%, 25.3%) |
| PPV-1 | 14.9% | 18.9% | 4.0% (3.7%, 4.4%) |
| Subgroup of women with calcification-related lesions (n = 660 women) | | | |
| Lesion-specific sensitivity | 98.1% | 91.7% | 6.4% (3.1%, 10.8%) |
| Non-FPR | 21.2% | 34.8% | 13.6% (11.2%, 16.5%) |
| PPV-1 | 22.9% | 25.1% | 2.3% (1.7%, 2.8%) |

Lesion-specific sensitivity: proportion of detected malignant lesions; non-FPR: proportion of women without any false-positive ratings out of all women; PPV-1: positive predictive value of recall; 95% CI: 95% confidence interval
detected malignant lesions to be missed (score 0), but in turn prevented 30.1% of false-positive recalls in our study.

This study is not without limitations. Although we used consecutive screens reflecting the screening population of recalled women in practice, our findings might be limited by the use of retrospective exams of one screening unit. Furthermore, in clinical practice, it can be expected that the AI system would be used to guide the final decision of radiologists to recall a patient, rather than as a stand-alone step on which the decision would be based on. Prospective studies to address this issue are desirable to

Fig. 3 Distribution of recalled malignant (a) and recalled benign (b) lesions as a function of the AI score, representing the likelihood of breast cancer (0, 27, 28, ..., 95).
estimate the effect of using AI in a key decision process of a mammography screening program.

The retrospective study was not designed to test a potential increase in cancer detection or false-positive recalls, as AI was not applied to all cases discussed during consensus conference. The reported performance measures are therefore related to a specific study setting.

In contrast to the AI system used in this study, radiologists had access to prior exams (not processed by the current AI version), if available, that could have impacted their decision to recall a patient. Future software developments as the inclusion of priors might improve the diagnostic performance of the AI system.

In conclusion, the AI system was able to increase discrimination of recalled benign from recalled malignant lesions, thereby increasing the positive predictive value of recall at the expense of some sensitivity loss. Whether this loss of sensitivity can be traded off for a reduction in false-positive recall is an important clinical consideration which cannot be answered by the study as those early-stage cancers might be relevant to improve survival. Application of the AI system to aid the decision to recall a woman seems, however, beneficial especially for masses, where the system reached comparable sensitivity to that of the readers, but with considerably reduced false-positives. Prospective clinical studies are needed to investigate to which extent the potential benefits of AI in breast cancer screening translate into clinical practice.

Funding Open Access funding enabled and organized by Projekt DEAL. This study has received funding by the European Union (EU) (Programm Deutschland-Nederland): INTERREG V A-Projekt “InMediValue” (122207).

Declarations

Guarantor The scientific guarantor of this publication is Walter Heindel.

Conflict of interest The authors of this manuscript declare relationships as project partners of the EU-funded INTERREG V A-Projekt with the following companies: ScreenPoint Medical BV, Nijmegen, The Netherlands (AR and NK are employees).

Statistics and biometry One of the authors (LK) has significant statistical expertise.

Informed consent Written informed consent was not required for this study due to the evaluation of internal anonymized data.

Ethical approval Institutional Review Board approval was obtained.

Methodology

- retrospective
- diagnostic study/experimental
- performed at one institution

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Lee CI, Houssami N, Elmore JG, Buist DSM (2019) Pathways to breast cancer screening artificial intelligence algorithm validation. Breast 52:146–149
2. Yala A, Schuster T, Miles R, Barzilay R, Lehman C (2019) A deep learning model to triage screening mammograms: a simulation study. Radiology 293:38–46
3. Rodríguez-Ruiz A, Krupinski E, Mordang JJ et al (2019) Detection of breast cancer with mammography: effect of an artificial intelligence support system. Radiology 290:305–314
4. Rodriguez-Ruiz A, Lång K, Gubern-Merida A et al (2019) Can we reduce the workload of mammographic screening by automatic identification of normal exams with artificial intelligence? A feasibility study. Eur Radiol 29:4825–4832
5. Schaffter T, Buist DSM, Lee CI et al (2020) Evaluation of combined artificial intelligence and radiologist assessment to interpret mammograms. JAMA Netw Open 3:e200265
6. McKinney SM, Sieniek M, Godbole V et al (2020) International evaluation of an AI system for breast cancer screening. Nature 577:89–94
7. Geras KJ, Mann RM, Moy L (2019) Artificial intelligence for mammography and digital breast tomosynthesis: current concepts and future perspectives. Radiology 293:246–259
8. Houssami N, Kirkpatrick-Jones G, Noguchi N, Lee CI (2019) Artificial Intelligence (AI) for the early detection of breast cancer: a scoping review to assess AI’s potential in breast screening practice. Expert Rev Med Device 16:351–362
9. Le EPV, Wang Y, Huang Y, Hickman S, Gilbert FJ (2019) Artificial intelligence in breast imaging. Clin Radiol 74:357–366
10. Kim HE, Kim HH, Han BK et al (2020) Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study. Lancet Digit Health 2:e138–e148
11. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M (2013) The benefits and harms of breast cancer screening: an independent review. Br J Cancer 108:2205–2240
12. Tosteson AN, Fryback DG, Hammond CS et al (2014) Consequences of false-positive screening mammograms. JAMA Intern Med 174:954–961
13. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, van Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg
14. Kooperationsgemeinschaft Mammographie (2020) Jahresbericht Evaluation 2018 Deutsches Mammographie-Screening-Programm. Available via https://fachservice.mammo-programm.de/download/evaluationsberichte/Jahresbericht-Evaluation_2018.pdf. Accessed 19 Jan 2021.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.